Encoded Therapeutics announced that the first participant has been dosed in a pivotal clinical trial testing ETX101, the company’s experimental one-time gene therapy for Dravet syndrome, which is recruiting children and adolescents with this severe form of epilepsy. The pivotal study is the second part of the…
News
Diseases that mimic Dravet syndrome symptoms are usually caused by mutations in genes other than SCN1A — the gene most often mutated in Dravet — and identifying the exact genetic cause, through testing, is key to guiding appropriate treatment strategies, according to a new study from China. While most…
Beyond reducing seizures, add-on treatment with Fintepla (fenfluramine) may improve daily functioning in areas such as communication, attention, and awareness of surroundings in adults and children with Dravet syndrome, especially younger patients and those who engage more frequently in rehabilitation, an Italian study found. “Caregivers noticed meaningful improvements in…
Caregivers of people with Dravet syndrome frequently experience significant mental health challenges, including anxiety and depression, sleep problems, fatigue, stress, and social isolation, according to a systematic review of studies. The findings, published in the journal Epilepsy, highlight the emotional burden placed on caregivers and underscore the need for routine assessment…
Astrocytes change how they connect and function in a mouse model of Dravet syndrome — even without visible brain damage — which likely worsens seizures and cognitive problems, making them a potential target for future treatments, according to a study. These support cells in the brain help…
Dysfunction in mitochondria — the cell’s energy production centers — was frequently seen in children with developmental and epileptic encephalopathies (DEEs), including Dravet syndrome, even when mitochondrial disease was not the underlying cause, a new study found. Many children with these genetic conditions, which are marked by early-onset seizures…
Encoded Therapeutics has met with the U.S. Food and Drug Administration (FDA) and the two have aligned on the design of a pivotal clinical trial to support a potential approval filing for ETX101, a one-time gene therapy designed to address the underlying cause of Dravet syndrome. ETX101 is…
People with Dravet syndrome should receive all routine vaccinations recommended for their age, but careful strategies are needed to reduce the risk of fever-related seizures, a study reported. The researchers suggested practical approaches to manage fever in Dravet patients, but noted that further studies are needed to develop guidelines…
A clinical study showed that Soticlestat, when added to standard treatment, tended to reduce convulsive seizures in children and young adults with Dravet syndrome compared with a placebo, although the study “narrowly missed” its main statistical goal, according to research led by Takeda Pharmaceuticals. The company decided last…
Problems with sleep and body temperature regulation in Dravet syndrome are linked through the hypothalamus — the part of the brain that regulates both — and targeting it may help develop better treatments, according to a study in a mouse model of the disease. “These findings highlight a connection between…
Recent Posts
- Pivotal trial of Dravet syndrome gene therapy begins, now enrolling children
- Is it Dravet? SCN1A gene testing provides answers, guides treatment.
- I didn’t stop being a mom when my child with Dravet syndrome died
- Add-on Fintepla may improve daily functioning in Dravet syndrome: Study
- The stress of caring for a child with special needs affected my health